Discovery of biaryl-4-carbonitriles as antihyperglycemic agents that may act through AMPK-p38 MAPK pathway

Molecular and Cellular Endocrinology

Volumn 394, Issue 1-2, 2014, Pages 1-12

  Goel, Atul ^a   Nag, Pankaj ^a   Rahuja, Neha ^a   Srivastava, Rohit ^a   Chaurasia, Sumit ^a   Gautam, Sudeep ^a   Chandra, Sharat ^a   Siddiqi, Mohammad Imran ^a   Srivastava, Arvind K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Anti hyperglycemic activity; Biaryls; Gene expression; Glucose uptake; PTP1B

Indexed keywords

4' BROMO 2,3 DIMETHYL 5 (PIPERIDIN 1 YL)BIPHENYL 4 CARBONITRILE; ADENYLATE KINASE; BIARYL 4 CARBONITRILE; DEOXYGLUCOSE; GLUCOSE; GLUCOSE TRANSPORTER 4; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPERGLYCEMIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SITAGLIPTIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2; 40-BROMO-2,3-DIMETHYL-5-(PIPERIDIN-1-YL)BIPHENYL-4-CARBONITRILE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; HEPATOCYTE NUCLEAR FACTOR 4; HNF4A PROTEIN, RAT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; ION CHANNEL; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL UNCOUPLING PROTEIN 2; NITRILE; SLC2A4 PROTEIN, RAT; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CARBOHYDRATE TRANSPORT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BINDING SITE; DRUG EFFECT; DRUG SCREENING; DRUG SYNTHESIS; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLUT 4 GENE; HNF4 ALPHA GENE; HYDROGEN BOND; IC 50; MALE; MOLECULAR INTERACTION; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PPAR ALPHA GENE; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UCP2 GENE; UPREGULATION; ANIMAL; BLOOD; C57BL MOUSE; CELL LINE; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HYPERGLYCEMIA; METABOLISM; MOUSE; SKELETAL MUSCLE; SYNTHESIS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD GLUCOSE; CELL LINE; CHOLESTEROL, HDL; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION REGULATION; GLUCOSE TRANSPORTER TYPE 4; HEPATOCYTE NUCLEAR FACTOR 4; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; ION CHANNELS; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIAL PROTEINS; MODELS, MOLECULAR; MUSCLE FIBERS, SKELETAL; NITRILES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PPAR ALPHA; RATS; SIGNAL TRANSDUCTION; STREPTOZOCIN; TRIGLYCERIDES;

EID: 84904364548     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.06.007     Document Type: Article

References (91)

1. Andersen J.N., Mortensen O.H., Peters G.H., Drake P.G., Iversen L.F., Olsen O.H., Jansen P.G., Andersen H.S., Tonks N.K., Møller N.P.H. Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol. Cell. Biol. 2001, 21:7117-7136.
2. Anthony J., Kelkar A., Wilankar C., Ranjith V., Bhumra S.K., Mutt S., Deka N., Sivaramakrishnan H., Sharma S., Marita A.R. Discovery of P1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models. PLoS ONE 2013, 8:1-10.
3. Bento J.L., Palmer N.D., Mychaleckyj J.C., Lange L.A., Langefeld C.D., Rich S.S., Freedman B.I., Bowden D.W. Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 diabetes. Diabetes 2004, 53:3007-3012.
4. Bloomgarden Z.T. Diabetic neuropathy. Diabetes Care 2008, 31:616-621.
5. Bril V. Treatments for diabetic neuropathy. J. Peripher. Nerv. Syst. 2012, 17:22-27.
6. Calera M.R., Vallega G., Pilch P.F. Dynamics of protein-tyrosine phosphatases in rat adipocytes. J. Biol. Chem. 2000, 275:6308-6312.
7. Chittiboyina A.G., Venkatraman M.S., Mizuno C.S., Desai P.V., Patny A., Benson S.C., Ho C.I., Kurtz T.W., Pershadsingh H.A., Avery M.A. Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARγ agonists. J. Med. Chem. 2006, 49:4072-4084.
8. Cincinelli R., Dallavalle S., Nannei R., Carella S., Zani D.D., Merlini L., Penco S., Garattini E., Giannini G., Pisano C., Vesci L., Carminati P., Zuco V., Zanchi C., Zunino F. Synthesis and structure-activity relationships of a new series of retinoid-related biphenyl-4-ylacrylic acids endowed with antiproliferative and proapoptotic activity. J. Med. Chem. 2005, 48:4931-4946.
9. Combs A.P., Zhu W., Crawley M.L., Glass B., Polam P., Sparks R.B., Modi D., Takvorian A., McLaughlin E., Yue E.W., Wasserman Z., Bower M., Wei M., Rupar M., Ala P.J., Reid B.M., Ellis D., Gonneville L., Emm T., Taylor N., Yeleswaram S., Li Y., Wynn R., Burn T.C., Hollis G., Liu P.C.C., Metcalf B. Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic. J. Med. Chem. 2006, 49:3774-3789.
10. Di Paola R., Frittitta L., Miscio G., Bozzali M., Baratta R., Centra M., Spampinato D., Santagati M.G., Ercolino T., Cisternino C., Soccio T., Mastroianno S., Tassi V., Almgren P., Pizzuti A., Vigneri R., Trischitta V. A variation in 3' UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am. J. Hum. Genet. 2002, 70:806-812.
11. Dixit M., Saeed U., Kumar A., Siddiqi M.I., Tamrakar A.K., Srivastava A.K., Goel A. Synthesis, molecular docking and PTP1B inhibitory activity of functionalized 4,5-dihydronaphthofurans and dibenzofurans. Med. Chem. 2008, 4:18-24.
12. Dixit M., Tripathi B.K., Srivastava A.K., Goel A. Synthesis of functionalized acetophenones as protein tyrosine phosphatase 1B inhibitors. Bioorg. Med. Chem. Lett. 2005, 15:3394-3397.
13. Dixit M., Tripathi B.K., Tamrakar A.K., Srivastava A.K., Kumar B., Goel A. Synthesis of benzofuran scaffold-based potential PTP-1B inhibitors. Bioorg. Med. Chem. 2007, 15:727-734.
14. Duval C., Müller M., Kersten S. PPARα and dyslipidemia. Biochim. Biophys. Acta 2007, 1771:961-971.
15. Fenwick E., Rees G., Pesudovs K., Dirani M., Kawasaki R., Wong T.Y., Lamoureux E. Social and emotional impact of diabetic retinopathy: a review. Clin. Exp. Ophthalmol. 2012, 40:27-38.
16. Ferreira S.B., Sodero A.C.R., Cardoso M.F.C., Lima E.S., Kaiser C.R., Silva F.P., Ferreira V.F. Synthesis, biological activity, and molecular modeling studies of 1H-1,2,3-triazole derivatives of carbohydrates as α-glucosidases inhibitors. J. Med. Chem. 2010, 53:2364-2375.
17. Fleury C., Neverova M., Collins S., Raimbault S., Champigny O., Levi-Meyrueis C., Bouillaud F., Seldin M.F., Surwit R.S., Ricquier D., Warden C.H. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat. Genet. 1997, 15:269-272.
18. Fragiadaki M., Hill N., Hewitt R., Bou-Gharios G., Cook T., Tam F.W., Domin J., Mason R.M. Hyperglycemia causes renal cell damage via CCN2-induced activation of the TrkA receptor: implications for diabetic nephropathy. Diabetes 2012, 61:2280-2288.
19. Goel A., Agarwal N., Singh F.V., Sharon A., Tiwari P., Dixit M., Pratap R., Srivastava A.K., Maulik P.R., Ram V.J. Antihyperglycemic activity of 2-methyl-3,4,5-triaryl-1H-pyrroles in SLM and STZ models. Bioorg. Med. Chem. Lett. 2004, 14:1089-1092.
20. Goel A., Chaurasia S., Dixit M., Kumar V., Prakash S., Jena B., Verma J.K., Jain M., Anand R.S., Manoharan S.S. Donor-acceptor 9-uncapped fluorenes and fluorenones as stable blue light emitters. Org. Lett. 2009, 11:1289-1292.
21. Goel A., Dixit M., Chaurasia S., Kumar A., Raghunandan R., Maulik P.R., Anand R.S. Vapor-phase processable novel nonplanar donor-acceptor quateraryls for blue OLEDs. Org. Lett. 2008, 10:2553-2556.
22. Goel A., Kumar V., Nag P., Bajpai V., Kumar B., Singh C., Prakash S., Anand R.S. Thermally stable nonaggregating pyrenylarenes for blue organic light-emitting devices. J. Org. Chem. 2011, 76:7474-7481.
23. Goel A., Kumar V., Singh S.P., Sharma A., Prakash S., Singh C., Anand R.S. Non-aggregating solvatochromic bipolar benzo[f]quinolines and benzo[a]acridines for organic electronics. J. Mater. Chem. 2012, 22:14880-14888.
24. Goel A., Verma D., Dixit M., Raghunndan R., Maulik P.R. Acetyltrimethylsilane: a novel reagent for the transformation of 2H-Pyran-2-ones to unsymmetrical biaryls. J. Org. Chem. 2006, 71:804-807.
25. Goldstein B.J., Bittner-Kowalczyk A., White M.F., Harbeck M. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. J. Biol. Chem. 2000, 275:4283-4289.
26. Hainer V., Toplak H., Mitrakou A. Treatment modalities of obesity: what fits whom?. Diabetes Care 2008, 31:S269-S277.
27. Herzig S., Long F., Jhala U.S., Hedrick S., Quinn R., Bauer A., Rudolph D., Schutz G., Yoon C., Puigserver P., Spiegelman B., Montminy M. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 2001, 413:179-183.
28. Huttunen K.M., Mannila A., Laine K., Kemppainen E., Leppanen J., Vepsalainen J., Jarvinen T., Rautio J. The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption. J. Med. Chem. 2009, 52:4142-4148.
29. Hyvärinen M., Qiao Q., Tuomilehto J., Laatikainen T., Heine R.J., Stehouwer C.D.A., Alberti K.G.M.M., Pyörälä K., Zethelius B., Stegmayr B. Hyperglycemia and stroke mortality. Diabetes Care 2009, 32:348-354.
30. Jiang B., Guo S., Shi D., Guo C., Wang T. Discovery of novel bromophenol 3,4-dibromo-5-(2-bromo-3,4-dihydroxy-6-(isobutoxymethyl)benzyl)benzene-1,2-diol as protein tyrosine phosphatase 1B inhibitor and its anti-diabetic properties in C57BL/KsJ-db/db mice. Eur. J. Med. Chem. 2013, 64:129-136.
31. Kanatani Y., Usui I., Ishizuka K., Bukhari A., Fujisaka S., Urakaze M., Haruta T., Kishimoto T., Naka T., Kobayashi M. Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes 2007, 56:795-803.
32. Kipfer-Coudreau S., Eberlé D., Sahbatou M., Bonhomme A., Guy-Grand P., Froquel P., Galan P., Basdevant A., Clément K. Single nucleotide polymorphisms of protein tyrosine phosphatase 1B gene are associated with obesity in morbidly obese French subjects. Diabetologia 2004, 47:1278-1284.
33. Konrad D., Somwar R., Sweeney G., Yaworsky K., Hayashi M., Ramlal T., Klip A. The antihyperglycemic drug α-Lipoic acid stimulates glucose uptake via both GLUT4 translocation and GLUT4 activation: potential role of p38 mitogen-activated protein kinase in GLUT4 activation. Diabetes 2001, 50:1464-1471.
34. Kurundkar S.B., Sachan N., Kodam K.M., Kulkarni V.M., Bodhankar S.L., D'souza S., Vanage G., Ghole V.S. Novel biphenyl compound, VMNS2e, ameliorates streptozotocin-induced diabetic nephropathy in rats. J. Diabetes 2010, 2:282-289.
35. Kurundkar S.B., Sachan N., Kodam K.M., Kulkarni V.M., Bodhankar S.L., Ghole V.S. VMNS2e: a potential biphenyl PTP1B inhibitor, suppresses the development of diabetic retinopathy in STZ induced diabetic rats. Pharmacologia 2011, 2:237-245.
36. Lee S.H., Seo H.J., Lee S.H., Jung M.E., Park J.H., Park H.J., Yoo J., Yun H., Na J., Kang S.Y., Song K.S., Kim M.-A., Chang C.H., Kim J., Lee J. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity. J. Med. Chem. 2008, 51:7216-7233.
37. Li C., He X.P., Zhang Y.J., Li Z., Gao L.X., Shi X.X., Xie J., Li J., Chen G.R., Tang Y. Click to a focused library of benzyl 6-triazolo(hydroxy)benzoic glucosides: novel construction of PTP1B inhibitors on a sugar scaffold. Eur. J. Med. Chem. 2011, 46:4212-4218.
38. Liu P., Zhu S., Li P., Xie W., Jin Y., Sun Q., Wu Q., Sun P., Zhang Y., Yang X., Jiang Y., Zhang D. Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents. Bioorg. Med. Chem. Lett. 2008, 18:3261-3265.
39. Love-Gregory L., Permutt M.A. HNF4A genetic variants: role in diabetes. Curr. Opin. Clin. Nutr. Metab. Care 2007, 10:397-402.
40. Makino H., Miyamoto Y., Sawai K., Mori K., Mukoyama M., Nakao K., Yoshimasa Y., Suga S.-I. Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes 2006, 55:2747-2756.
41. Malamas M.S., Sredy J., Moxham C., Katz A., Xu W., McDevitt R., Adebayo F.O., Sawicki D.R., Seestaller L., Sullivan D., Taylor J.R. Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties. J. Med. Chem. 2000, 43:1293-1310.
42. Martens F.M.A.C., Visseren F.L.J., Lemay J., De Koning E.J.P., Rabelink T.J. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002, 62:1463-1480.
43. Matsumoto S., Yoshida T., Murata H., Harada S., Fujita N., Nakamura S., Yamamoto Y., Watanabe T., Yonekura H., Yamamoto H., Ohkubo T., Kobayashi Y. Solution structure of the variable-type domain of the receptor for advanced glycation end products: new insight into AGE-RAGE interaction. Biochemistry 2008, 47:12299-12311.
44. McBriar M.D., Guzik H., Xu R., Paruchova J., Li S., Palani A., Clader J.W., Greenlee W.J., Hawes B.E., Kowalski T.J., O'Neill K., Spar B., Weig B. Discovery of bicycloalkyl urea melanin concentrating hormone receptor antagonists: orally efficacious antiobesity therapeutics. J. Med. Chem. 2005, 48:2274-2277.
45. Miyamato Y., Banno Y., Yamashita T., Fujimoto T., Oi S., Moritoh Y., Asakawa T., Kataoka O., Yashiro H., Takeuchi K., Suzuki N., Ikedo K., Kosaka T., Tsubotani S., Tani A., Sasaki M., Funami M., Amano M., Yamamoto Y., Aertgeerts K., Yano J., Maezaki H. Discovery of a 3-pyridylacetic acid derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor. J. Med. Chem. 2011, 54:831-850.
46. Mohler M.L., Kang G.-S., Hong S.-S., Patil R., Kirichenko O.V., Li W., Rakov I.M., Geisert E.E., Miller D.D. Discovery of antiglioma activity of biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues. J. Med. Chem. 2006, 49:5845-5848.
47. Morganstein D.L., Tan S., Gore M., Feher M.D. Prevalence of diabetes in patients admitted to a cancer hospital. Br. J. Diabetes Vasc. Dis. 2012, 12:178-180.
48. Morini G., Comini M., Rivara M., Rivara S., Bordi F., Plazzi P.V., Flammini L., Saccani F., Bertoni S., Ballabeni V., Barocelli E., Mor M. Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity. Bioorg. Med. Chem. 2008, 16:9911-9924.
49. Murage E.N., Gao G., Bisello A., Ahn J.M. Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. J. Med. Chem. 2010, 53:6412-6420.
50. Narender T., Sarkar S., Rajendar K., Tiwari S. Synthesis of biaryls via AlCl3 catalyzed domino reaction involving cyclization, dehydration, and oxidation. Org. Lett. 2011, 13:6140-6143.
51. Nicolaou K.C., Boddy C.N.C., Bräse S., Winssinger N. Chemistry, biology, and medicine of the glycopeptide antibiotics. Angew. Chem. Int. Ed. 1999, 38:2096-2152.
52. Ohtake Y., Sato T., Kobayashi T., Nishimoto M., Taka N., Takano K., Yamamoto K., Ohmori M., Yamaguchi M., Takami K., Yeu S.Y., Ahn K.H., Matsuoka H., Morikawa K., Suzuki M., Hagita H., Ozawa K., Yamaguchi K., Kato M., Ikeda S. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2012, 55:7828-7840.
53. Park M.H., Kinra S., Ward K.J., White B., Viner R.M. Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 2009, 32:1743-1745.
54. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25:1605-1612.
55. Pospisilik J.A., Martin J., Doty T., Ehses J.A., Pamir N., Lynn F.C., Piteau S., Demuth H.-U., McIntosh C.H.S., Pederson R.A. Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003, 52:741-750.
56. Pratley R.E., Salsali A., Matfin G. Inhibition of dipeptidyl peptidase-4 with vildagliptin: a potential new treatment for type 2 diabetes. Br. J. Diabetes Vasc. Dis. 2006, 6:150-156.
57. Quesnelle C.A., Gill P., Roy S., Dodier M., Marinier A., Martel A., Snyder L.B., D'Andrea S.V., Bronson J.J., Frosco M., Beaulieu D., Warr G.A., DenBleyker K.L., Stickle T.M., Yang H., Chaniewski S.E., Ferraro C.A., Taylor D., Russell J.W., Santone K.S., Clarke J., Drain R.L., Knipe J.O., Mosure K., Barrett J.F. Biaryl isoxazolinone antibacterial agents. Bioorg. Med. Chem. Lett. 2005, 15:2728-2733.
58. Ram V.J. Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation. Prog. Drug Res. 2003, 60:93-132.
59. Rathish I.G., Javed K., Bano S., Ahmad S., Alam M.S., Pillai K.K. Synthesis and blood glucose lowering effect of novel pyridazinone substituted benzenesulfonylurea derivatives. Eur. J. Med. Chem. 2009, 44:2673-2678.
60. Rosen E.D., MacDougald O.A. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 2006, 7:885-896.
61. Saltiel A.R., Pessin J.E. Insulin signaling pathways in time and space. Trends Cell Biol. 2002, 12:65-71.
62. Sander D., Sander K., Poppert H. Stroke in type 2 diabetes. Br. J. Diabetes Vasc. Dis. 2008, 8:222-229.
63. Schultze S.M., Hemmings B.A., Niessen M., Tschopp O. PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Expert Rev. Mol. Med. 2012, 14:1-21.
64. Scully T. Diabetes in numbers. Nature Outlook 2012, 485:S2-S3.
65. Seewoodhary J., Bain S.C. Diabetes, diabetes therapies and cancer: what's the link. Br. J. Diabetes Vasc. Dis. 2011, 11:235-238.
66. Sharon A., Pratap R., Vatsyayan R., Maulik P.R., Roy U., Goel A., Ram V.J. 6-Aryl-4-methylsulfanyl-2H-pyran-2-one-3-carbonitriles as PPAR-γ activators. Bioorg. Med. Chem. Lett. 2005, 15:3356-3360.
67. Singh F.V., Chaurasia S., Joshi M.D., Srivastava A.K., Goel A. Synthesis and in vivo antihyperglycemic activity of nature-mimicking furanyl-2-pyranones in STZ-S model. Bioorg. Med. Chem. Lett. 2007, 17:2425-2429.
68. Singh F.V., Parihar A., Chaurasia S., Singh A.B., Singh S.P., Tamrakar A.K., Srivastava A.K., Goel A. 5,6-Diarylanthranilo-1,3-dinitriles as a new class of antihyperglycemic agents. Bioorg. Med. Chem. Lett. 2009, 19:2158-2161.
69. Somwar R., Kim D.Y., Sweeney G., Huang C., Niu W., Lador C., Ramlal T., Klip A. GLUT4 translocation precedes the stimulation of glucose uptake by insulin in muscle cells: potential activation of GLUT4 via p38 mitogen-activated protein kinase. Biochem. J. 2001, 359:639-649.
70. Spiegelman B.M. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47:507-514.
71. Stierand K., Rarey M. Drawing the PDB: protein-ligand complexes in two dimensions. ACS Med. Chem. Lett. 2010, 1:540-545.
72. Sun L.P., Shen Q., Piao H.H., Ma W.P., Gao L.X., Zhang W., Nan F.J., Li J., Piao H.R. Synthesis and biological evaluation of (±)-3-(2-(2-fluorobenzyloxy)naphthalen-6-yl)-2-aminopropanoic acid derivatives as novel PTP1B inhibitors. Eur. J. Med. Chem. 2011, 46:3630-3638.
73. SYBYL, Molecular Modeling System. [7.1] (2006) TRIPOS, Assoc, Inc. St-Louis, MO.
74. Tiwari P., Rahuja N., Kumar R., Lakshmi V., Srivastava M.N., Agarwal S.C., Raghubir R., Srivastava A.K. Search for antihyperglycemic activity in few marine flora and fauna. Indian. J. Sci. Technol. 2008, 1:1-5.
75. Tominaga Y., Ushirogochi A., Matsuda Y., Kobayashi G. Synthesis and reactions of 6-aryl- and 6-styryl-3-cyano-4-methylthio-2H-pyran-2-ones. Chem. Pharm. Bull. 1984, 32:3384-3395.
76. Tonks N.K. PTP1B: from the sidelines to the front lines. FEBS Lett. 2003, 546:140-148.
77. Tsuchiya K., Accili D. Liver sinusoidal endothelial cells link hyperinsulinemia to hepatic insulin resistance. Diabetes 2013, 62:1478-1489.
78. Turner N.C., Clapham J.C. Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Prog. Drug Res. 1998, 51:33-94.
79. Wein S., Schrader E., Rimbach G., Wolffram S. Oral quercetin supplementation lowers plasma sICAM-1 concentrations in female db/db Mice. Pharmacol. Pharm. 2013, 4:77-83.
80. Wierzbicki A.S. The fats of life in diabetes. Br. J. Diabetes Vasc. Dis. 2012, 12:216-220.
81. Williams D.H., Bardsley B. The vancomycin group of antibiotics and the fight against resistant bacteria. Angew. Chem. Int. Ed. 1999, 38:1172-1193.
82. Wright J., Vardhan A. The problem of diabetic nephropathy and practical prevention of its progression. Br. J. Diabetes Vasc. Dis. 2008, 8:272-277.
83. Xi X., Han J., Zhang J.-Z. Stimulation of glucose transport by AMP-activated protein kinase via activation of p38 mitogen-activated protein kinase. J. Biol. Chem. 2001, 276:41029-41034.
84. Yang C., Cross K., Myatt G.J., Blower P.E., Rathman J.F. Building predictive models for protein tyrosine phosphatase 1B inhibitors based on discriminating structural features by reassembling medicinal chemistry building blocks. J. Med. Chem. 2004, 47:5984-5994.
85. Yin L., Liebscher J. Carbon-carbon coupling reactions catalyzed by heterogeneous palladium catalysts. Chem. Rev. 2007, 107:133-173.
86. Yoon J.C., Puigserver P., Chen G., Donovan J., Wu Z., Rhee J., Adelmant G., Stafford J., Kahn C.R., Granner D.K., Newgard C.B., Spiegelman B.M. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001, 413:131-138.
87. Zabolotny J.M., Haj F.G., Kim Y.B., Kim H.J., Shulman G.I., Kim J.K., Neel B.G., Kahn B.B. Transgenic over expression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but over expression with leukocyte antigen-related phosphatase does not additively impair insulin action. J. Biol. Chem. 2004, 279:24844-24851.
88. Zhang S., Zhang Z.Y. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discovery Today 2007, 12:373-381.
89. Zhang Y., Zhou B., Deng B., Zhang F., Wu J., Wang Y., Le Y., Zhai Q. Amyloid-β induces hepatic insulin resistance in vivo via JAK2. Diabetes 2013, 62:1159-1166.
90. Zhang Z.Y., Maclean D., McNamara D.J., Sawyer T.K., Dixon J.E. Protein tyrosine phosphatase substrate specificity: size and phosphotyrosine positioning requirements in peptide substrates. Biochemistry 1994, 33:2285-2290.
91. Zhou J., Bhattacharjee A., Chen S., Chen Y., Duffy E., Farmer J., Goldberg J., Hanselmann R., Ippolito J.A., Lou R., Orbin A., Oyelere A., Salvino J., Springer D., Tran J., Wang D., Wu Y., Johnson G. Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics. Bioorg. Med. Chem. Lett. 2008, 18:6175-6178.